You searched for Gout - Page 6 of 90

Abstract Number: 0240 • ACR Convergence 2023
Gout: A Gateway to Chronic Opioid Use?
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Tuhina Neogi², James O'Dell¹ and Ted R Mikuls³, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Painful gout flares often lead to healthcare visits which, based on prior reports, results in the use of opioid therapy for flare management, despite…
Abstract Number: 0241 • ACR Convergence 2023
Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
Austin Barry¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Bridget Kramer¹, Jeff Newcomb⁴, Mary Brophy³, Anne Davis-Karim⁵, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, James O'Dell¹ and Ted R Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Boston VA, Boston, MA, ⁴Omaha VA, Omaha, NE, ⁵Albuquerque VA, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Initiating urate-lowering therapy (ULT) in gout is known to precipitate flares, which can lead to decreased adherence and suboptimal outcomes. Until recently, there has…
Abstract Number: 0242 • ACR Convergence 2023
Venous Thromboembolism in Patients with Gout in the US
Alka Mithal¹, Maanek Sehgal¹, Brian LaMoreaux² and Gurkirpal Singh¹, ¹ICORE, Woodside, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Venous thromboembolism (VTE), manifested by deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common medical problem with an estimated incidence of 1–2…
Abstract Number: 0243 • ACR Convergence 2023
Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center
Nishah Panchani¹, Angelo Gaffo² and Vineeta Kumar³, ¹Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Arlington, TX, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL, ³Division of Nephrology/Transplant, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout has been associated with high rates of morbidity and mortality in kidney transplant (KT) patients with increased bone destruction and associated cardiovascular and…
Abstract Number: 0244 • ACR Convergence 2023
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
James Cheng-Chung Wei¹, Roy Fleischmann², sarah Morris³, Vijay Hingorani⁴, Elizabeth Polvent⁵, Zancong Shen⁶, Shunqi Yan⁷, Li-Tain Yeh⁸ and Robert Keenan⁹, ¹Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ²Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Arthrosi Therapeutics, San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁸Arthrosi Therapeutics, Inc., Irvine, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC
Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized,…
Abstract Number: 0245 • ACR Convergence 2023
Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
Claudia Maria Gomez¹, Patricio Cardoso Peñafiel¹, Jose Antonio Angel-Sesmero¹, Marta Novella-Navarro² and Enrique Calvo-Aranda¹, ¹Hospital Universitario Infanta Leonor, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Gout is associated with increased cardiovascular risk (CVR). Traditional CVR factors (CVRF) are frequently present in patients with gout, further worsening the prognosis. Several…
Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Herbert Baraf¹, Alan Kivitz², Sheri Rhodes³, Sheldon Leung⁴, Olu Folarin⁴, Tania Gonzalez-Rivera⁵, Joanna Sobierska⁵, Jacquie Christie⁵, Anand Patel⁶, Wesley DeHaan⁴, Rehan Azeem⁴ and Peter Traber⁷, ¹The Center for Rheumatology and Bone Research, George Washington University, Rheumatology, Bethesda, MD, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Atlanta, GA, ⁴Selecta Biosciences, Inc., Watertown, MA, ⁵Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden, ⁶Pioneer Research Solutions, Houston, TX, ⁷Selecta Biosciences, Gladwyne, PA
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…
Abstract Number: 0247 • ACR Convergence 2023
Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States
Sheryl Kluberg¹, Andrew Simon², Sarah Alam², Alexander Peters², Casie Horgan², Dongdong Li², Érick Moyneur³, Richard Platt², Cheryl N McMahill-Walraven⁴, Djeneba Audrey Djibo⁴, Qianli Ma⁵, Mano Selvan⁵, Claire Pernar⁶, Najat Ziyadeh⁶, Aziza Jamal-Allial⁷, Kimberly Daniels⁷, O’Mareen Spence⁸, Driss Oraichi⁸, Harry Seifert⁸, Valentine Franck⁹, Susan Gamble⁸ and Huifeng Yun⁸, ¹Harvard Medical School and Harvard Pilgrim Health Care Institute, Newton, MA, ²Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ³StatLog Inc, Quebec City, QC, Canada, ⁴CVS Health, Blue Bell, PA, ⁵Humana Healthcare Research, Inc., Louisville, KY, ⁶Optum, Baltimore, MD, ⁷Carelon Research, Boston, MA, ⁸GlaxoSmithKline, Rockville, MD, ⁹GlaxoSmithKline, Wavre, Belgium
Background/Purpose: Pre-licensure clinical trials for recombinant zoster vaccine (RZV) identified more frequent gout diagnoses among recipients of RZV than placebo; however, these trials were not…
Abstract Number: 0248 • ACR Convergence 2023
In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout
Panagiota Drivelegka¹, Lennart Jacobsson², Tatiana Zverkova-Sandström³ and Mats Dehlin⁴, ¹Department of Rheumatology, Sahlgrenska University hospital, Gothenburg, Sweden, ²University of Gothenburg, Malmö, Sweden, ³Institution of Medicine, Gothenburg, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Patients with gout are at increased risk of acute myocardial infarction (AMI). However, the clinical course, secondary prophylaxis and mortality after AMI has not…
Abstract Number: 0249 • ACR Convergence 2023
Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination Survey
Hyemin Jeong and Chan Hong Jeon, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea
Background/Purpose: Gout is associated with several comorbidities. The aim of this study was to evaluate the prevalence of comorbidities in Korean adult population with gout.…
Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Jie Wei¹, Hyon K. Choi², Nicola Dalbeth³, Xiaoxiao Li⁴, Changjun Li⁵, Chao Zeng⁶, Guanghua Lei⁶ and Yuqing Zhang⁷, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³University of Auckland, Auckland, New Zealand, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁷Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
Abstract Number: 0742 • ACR Convergence 2023
Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Natalie McCormick¹, Chio Yokose², Na Lu³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…
Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Natalie McCormick¹, Chio Yokose², Jie Wei³, Na Lu⁴, Deborah Wexler¹, Mary De Vera⁵, J. Antonio Avina-Zubieta⁴, Yuqing Zhang⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁷Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
Abstract Number: 0813 • ACR Convergence 2023
Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants
Mariano Andrés¹, Nalia Domínguez-Lirón², Enrique Calvo-Aranda³, Esther Vicente Rabaneda⁴, Agustín Martínez-Sanchís¹, Francisca Sivera⁵, Diana Peiteado⁶, Alejandro Prada⁷, Blanca Garcia⁸, Basilio Rodríguez⁹, BORIS ANTHONY BLANCO CACERES¹⁰, José Antonio Bernal¹¹, Santos Castañeda¹², Laura Barrio⁷, Sonia Minguez⁹, Mónica Vázquez Díaz¹³, José Miguel Senabre¹¹, Cristina Bohorquez¹⁴, Silvia Gómez-Sabater¹⁵, Rocío Caño-Alameda¹⁵ and Eugenio De Miguel¹⁶, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Elda General University Hospital, Elda, Spain, ⁶Hospital La Paz, Madrid, Spain, ⁷Hospital Universitario de Torrejón, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Fundació Althaia, Manresa, Spain, ¹⁰Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹¹Hospital Marina Baixa, Villajoyosa, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³Hospital Ramon y Cajal, Madrid, Spain, ¹⁴Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ¹⁵Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The prevalence of sonographic monosodium urate (MSU) crystal deposition and inflammation in patients with gout in remission is unknown. In 2022, we reported a…
Abstract Number: 0814 • ACR Convergence 2023
Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial
Joshua Qu¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Bridget Kramer¹, Jefferey Newcomb⁴, Mary Brophy³, Anne Davis-Karim⁵, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, James O'Dell¹ and Ted R Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Boston VA, Boston, MA, ⁴University of Nebraska, Omaha, NE, ⁵Albuquerque VA, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To optimally manage gout, the ACR recommends a treat-to-target (T2T) strategy, which entailsthe titration of urate-lowering therapy (ULT) to achieve and maintain a serum…

Gout: A Gateway to Chronic Opioid Use?

Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial

Venous Thromboembolism in Patients with Gout in the US

Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center

Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients

Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout

Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies

Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States

In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout

Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination Survey

Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study

Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes

Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study

Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants

Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial

Simple Search Results